Answers are grounded in this paper and cite their sources.
Despite the wide use of the antibody detection test for unexpected antibodies, controversy still remains regarding the use of enzyme-treated red blood cells. Over a 6-year period, 72,573 samples from 49,863 patients submitted for pretransfusion compatibility testing were examined for unexpected antibodies. The antibody detection tests included a low-ionic-strength solution (LISS) indirect antiglobulin test and a two-stage papain (2SP) test. One thousand and seventy of the 2267 (47%) antibodies tested by 2SP were reactive only by the 2SP test. Overall, the 2SP test detected only 0.6% of antibodies considered to be clinically significant (10 examples of anti-c and 2 examples of anti-e). The slight additional safety provided by detection of clinically-significant antibodies is overshadowed by the high number of clinically-insignificant antibodies detected by the 2SP test.
No takes yet. Share an insight, caveat, or question.
Castellà et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: